Cargando…
Biological Effects of Anti-RANKL Antibody and Zoledronic Acid on Growth and Tooth Eruption in Growing Mice
The anti-bone resorptive drugs denosumab, an anti-human-RANKL antibody, and zoledronic acid (ZOL), a nitrogen-containing bisphosphonate, have recently been applied for treatment of pediatric patients with bone diseases, though details regarding their effects in growing children have yet to be fully...
Autores principales: | Isawa, Motoki, Karakawa, Akiko, Sakai, Nobuhiro, Nishina, Saki, Kuritani, Miku, Chatani, Masahiro, Negishi-Koga, Takako, Sato, Masashi, Inoue, Mitsuko, Shimada, Yukie, Takami, Masamichi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6934544/ https://www.ncbi.nlm.nih.gov/pubmed/31882595 http://dx.doi.org/10.1038/s41598-019-56151-1 |
Ejemplares similares
-
Bone loss caused by dopaminergic degeneration and levodopa treatment in Parkinson’s disease model mice
por: Handa, Kazuaki, et al.
Publicado: (2019) -
Effects of lipid metabolism on mouse incisor dentinogenesis
por: Kurotaki, Yutaro, et al.
Publicado: (2020) -
The regulatory role of the RANKL/RANK/OPG signaling pathway in the mechanisms of tooth eruption in patients with impacted teeth
por: Brodetska, Ludmila, et al.
Publicado: (2020) -
Structural insights into the binding of zoledronic acid with RANKL via computational simulations
por: Wang, Ruijie, et al.
Publicado: (2022) -
Zoledronate Enhances Osteocyte-Mediated Osteoclast Differentiation by IL-6/RANKL Axis
por: Kim, Hyung Joon, et al.
Publicado: (2019)